India weighs red warning on cough syrup labels for under-4s

India's drug regulator is examining a proposal to print a red warning on cough syrup labels stating the medicine should not be used in children below four years, along with a pictorial of school-age children to discourage use in infants. The proposal, seeking changes to Rule 96 of the Drugs Rules, 1945, is before the Drugs Consultative Committee. A complaint said prescribing continued despite an October 2025 DGHS advisory against use below two years. A June 9 amendment made syrups prescription-only.

Written by AI from Times of India — Top · not yet reviewed by an editor · Published 20 Sept 2026, 12:58 pm IST

Source

Times of India — Top · read the original report ↗

#cough syrup#cdsco#drug regulation#child health#dghs

Desk check · compared with the source

What the desk checked (5)

India's drug regulator is examining a proposal for a red warning on cough syrup labels saying the product should not be used in children below four years — Attributed to a proposal 'seen by ET'; wording of the warning quoted in source, proposal not yet approved.
The proposal, submitted to the Drugs Consultative Committee, seeks changes to Rule 96 of the Drugs Rules, 1945, and suggests a pictorial of school-age children on labels — Figures and rule number appear in the source as part of the proposal document.
An October 2025 DGHS advisory recommended cough and cold medicines not be prescribed to children below two years, but the practice continued — Attributed to DGHS advisory plus an unnamed 'person familiar with the matter' and a complaint; individual not identified.
A CDSCO internal technical committee took up the issue in April 2026 and suggested consulting ICMR, which said it was not working on cough syrup labelling — Attributed to source narrative without named officials; internally consistent.
Drugs (Fifth Amendment) Rules, 2026, notified on June 9, removed 'syrups' from Schedule K, making a prescription mandatory — Attributed to the health ministry notification and dates given in source.

Written by AI from Times of India — Top · not yet reviewed by an editor · How we use AI · Report an error

Analysts’ view opinion

AI Policy Analyst

This is a classic case of a regulator moving from advice to design after advice failed to change behaviour. The October 2025 DGHS advisory asked prescribers to avoid cough and cold medicines in children under two, yet a complaint alleged the practice continued — so the proposed fix shifts the burden from the prescriber's discretion to the product itself, via a red warning and a pictorial cue on the label under Rule 96 of the Drugs Rules, 1945. Read alongside the June 9 amendment that pulled syrups out of Schedule K and made them prescription-only, a two-track strategy is visible: restrict access at the counter, and make the age limit unmissable on the bottle. The design logic is sound, but labelling is the weakest of enforcement tools if prescribing habits are the real driver.

The proposal's significance is that it is an admission that a soft-law advisory did not work — labelling is the harder, rule-based fallback, requiring an amendment to Rule 96 rather than a fresh circular.
The pictorial element targets a real gap advisories cannot reach: caregivers who dose at home and may not read or understand fine-print contraindications.
There is an unexplained threshold mismatch — the DGHS advice named children under two, while the label proposal names under four — and the story does not establish the clinical or administrative basis for the wider cut-off.
Sequencing matters: with syrups now out of Schedule K and prescription-only since June 9, a label warning mainly disciplines doctors and chemists, so the binding constraint becomes prescription audit and retail compliance, not printing.
Process has been reasonably deliberative — an internal CDSCO technical committee, a referral to ICMR (which said it has no such work underway), stakeholder consultation on marketing feasibility, and now the DCC — but each step adds delay to an issue flagged as ongoing.

What to watch — Watch whether the DCC clears the Rule 96 amendment and which age threshold survives — two or four — and whether it is paired with any mechanism to monitor paediatric prescribing and chemist-level compliance, without which the label risks being cosmetic.

The story does not establish how widespread under-age prescribing actually is, what evidence underpins the under-four threshold, whether the DCC will accept the proposal, or any timeline for implementation.

Deep dive

Research brief · 8 facts · 5 dates · exam-ready

The brief

Context

India's drug regulator is examining a proposal to redesign cough syrup labels so that they carry a prominent red warning against use in children below four years of age, along with a pictorial of school-age children to signal the product is not for infants and toddlers. The move follows continuing reports of cough syrups being prescribed to infants despite an October 2025 advisory from the Directorate General of Health Services (DGHS) against their use in children under two. Separately, the Union health ministry has already tightened access by removing syrups from the over-the-counter category through the Drugs (Fifth Amendment) Rules, 2026, notified on June 9, making a doctor's prescription mandatory.

Key facts

The proposal seen by ET would require the label to state: "WARNING: Cough syrup should not be used in children below 4 years of age", printed prominently in red.
It also proposes a pictorial depiction of school-age children on the bottle label to reinforce that the product is for older children.
The proposal has been submitted to the Drugs Consultative Committee (DCC) and seeks changes to Rule 96 of the Drugs Rules, 1945.
A DGHS advisory of October 2025 recommended that cough and cold medicines not be prescribed or dispensed to children below two years of age.
A complaint alleged cough syrups were still being prescribed to infants below two years even after the October 2025 DGHS directions.
An internal technical committee of CDSCO took up the issue in April 2026 and recommended consulting ICMR and stakeholders on labelling feasibility.
ICMR said it was not undertaking any work related to cough syrup labelling.
The Drugs (Fifth Amendment) Rules, 2026, notified on June 9, deleted the term "syrups" from Schedule K, making syrup medicines prescription-only.

Timeline

October 2025DGHS issues advisory urging caution in paediatric cough and cold medicine use and recommending no prescribing or dispensing below two years of age.
December 29, 2025Government issues draft notification seeking suggestions and objections from stakeholders and the public on the drug rules change.
April 2026An internal technical committee of CDSCO takes up the issue; recommends consulting ICMR and stakeholders on labelling changes.
June 9 (2026)Health ministry notifies the Drugs (Fifth Amendment) Rules, 2026, deleting "syrups" from Schedule K and making them prescription-only.
Current stageProposal for a red warning and pictorial on cough syrup labels is before the Drugs Consultative Committee for consideration.

Who has a stake

CDSCO (central drug regulator) — Examining the labelling proposal; its internal technical committee initiated consultation on regulatory and marketing feasibility.
Drugs Consultative Committee (DCC) — Must consider the proposed amendment to Rule 96 of the Drugs Rules, 1945, on label warnings.
Directorate General of Health Services (DGHS) — Issued the October 2025 advisory against paediatric use below two years, which reportedly continues to be flouted.
ICMR — Was proposed as a consultee but stated it is not working on cough syrup labelling.
Union health ministry — Notified the Drugs (Fifth Amendment) Rules, 2026 after consulting the Drugs Technical Advisory Board, tightening oversight of syrup medicines.
Parents, infants and young children — Directly exposed to risks from cough syrups prescribed or bought for very young children.
Doctors, chemists and pharmaceutical firms — Face changed prescribing, dispensing, packaging and marketing obligations for syrup formulations.

Why it matters

Cough syrups are among the most commonly prescribed and over-the-counter purchased medicines in India, and their use in very young children has long worried health experts. With an advisory alone proving insufficient, the regulator is moving towards binding label-level warnings and prescription-only status, shifting from persuasion to enforceable rules.

UPSC angle

Prelims pointers

Rule 96 of the Drugs Rules, 1945 governs labelling of medicines; the proposed red warning seeks an amendment to it.
Drugs Rules, 1945 are framed under the Drugs and Cosmetics Act, 1940 and govern manufacture, sale and distribution of medicines.
Schedule K lists medicine categories exempt from certain requirements under the Drugs and Cosmetics Act, 1940; "syrups" has now been deleted from it.
Drugs (Fifth Amendment) Rules, 2026 were notified on June 9, following a draft notification of December 29, 2025.
Drugs Technical Advisory Board (DTAB) is the country's apex technical body on drug regulation; it was consulted before the amendment.
DGHS advisory of October 2025 advised against prescribing or dispensing cough and cold medicines to children below two years.

Mains framing

The cough syrup labelling proposal illustrates a familiar regulatory gap in India: advisories exist but compliance at the point of prescription and sale is weak. Despite the DGHS advisory of October 2025 against paediatric use below two years, a complaint indicated that infants were still being prescribed these syrups, prompting a CDSCO technical committee in April 2026 to explore labelling reform and stakeholder consultation, even as ICMR clarified it had no work in this area. The response has taken two forms: a proposal before the Drugs Consultative Committee to amend Rule 96 of the Drugs Rules, 1945 so that bottles carry a prominent red warning against use below four years plus a pictorial of school-age children, and an already-notified amendment, the Drugs (Fifth Amendment) Rules, 2026 of June 9, deleting "syrups" from Schedule K so that they can no longer be sold over the counter. The implications span consumer safety, prescriber behaviour, pharmacy practice and industry packaging costs. A credible way forward, as suggested by the source, lies in combining enforceable labelling with stakeholder consultation on regulatory and marketing feasibility, strengthened oversight of syrup-based medicines, and effective enforcement of prescription-only sale rather than reliance on advisories alone.

Key terms

Rule 96, Drugs Rules, 1945: The provision on medicine labelling that the proposal seeks to amend to mandate the red under-4 warning.
Schedule K: Schedule under the Drugs and Cosmetics Act, 1940 listing medicine categories exempt from certain requirements; "syrups" has been deleted from it.
CDSCO: Central Drugs Standard Control Organisation, India's central drug regulator, whose internal technical committee examined the issue in April 2026.
Drugs Consultative Committee (DCC): Body to which the cough syrup labelling proposal has been submitted for consideration.
DGHS: Directorate General of Health Services, which issued the October 2025 advisory on paediatric cough and cold medicine use.
Drugs (Fifth Amendment) Rules, 2026: Health ministry notification of June 9 that removed syrup-based medicines from the over-the-counter category, requiring a prescription.

Practice questions

Advisories alone have failed to curb the use of cough syrups in infants in India. Examine how labelling mandates and prescription-only status can strengthen paediatric drug safety.
Discuss the institutional architecture of drug regulation in India with reference to CDSCO, DTAB and the Drugs Consultative Committee, using the cough syrup labelling proposal as an illustration.
What are the likely benefits and limitations of pictorial and colour-coded warnings on medicine packaging in a country with varied literacy levels?

Grounded only in the source report — figures and dates are the source's, not inferred.

Next storyThree killed as truck hits crane, auto-rickshaw in Sarita Vihar →

← All stories